Massilia shenzhen sp. nov., isolated from blood of one premature infant, causing sepsis
Year: 2024
Type: article
Study design: Case Report
Abstract: • A new potential opportunistic pathogen, Massilia shenzhen sp. nov., was identified. • Its drug-resistant genes, virulence factors are described base WGS sequence which will support further research to fully elucidate the pathogenesis of this novel species. This study explores a premature infant with respiratory failure and pneumonia, suggestive of neonatal sepsis. Despite initially negative clinical specimens, blood testing revealed a pathogen. MALDI-TOF-MS and physiological tests initially failed to identify it accurately. Subsequent analysis of the 16S rRNA gene, housekeeping genes, and whole genome sequencing placed it in the genus Massilia . Average Nucleotide Identities (ANIs) indicated 88.47 % similarity with the type strain of Massilia norwichensis . Detailed characterization showed it as Gram-negative, aerobic, flagellated, measuring 0.45–0.55 × 1.75–2.40 μm. Major fatty acids included C16:0, C16:1ω7c, C18:1ω7c, and cyclo-C17:0. Minimum inhibitory concentrations to ceftazidime, penicillin, and meropenem were <0.032 μg/mL, ≤0.75 μg/mL, and <0.002 μg/mL respectively. Phylogenetic analysis, fatty acid composition, and physiological parameters confirmed it as Massilia shenzhen sp. nov., with strain GZ0329 T . Given limited research on Massilia drug resistance, ceftazidime and imipenem show promise in treating Massilia infections.
Authors: Xinying Li, Wenxuan Zheng, Tongyu Hao, Ting Yang, Xiaojuan Gao, Xiuming Zhang
Language: English
Subfield: Endocrinology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,190
OpenAlex ID: W4403541268